Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,809,599
  • Shares Outstanding, K 50,860
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,820 K
  • 36-Month Beta -0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.33 +25.59%
on 11/01/17
37.50 -5.12%
on 10/23/17
+9.92 (+38.66%)
since 10/20/17
3-Month
19.01 +87.16%
on 08/24/17
37.50 -5.12%
on 10/23/17
+16.33 (+84.83%)
since 08/21/17
52-Week
15.97 +122.79%
on 05/31/17
37.50 -5.12%
on 10/23/17
+10.59 (+42.38%)
since 11/21/16

Most Recent Stories

More News
Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in...

AIMT : 35.58 (+2.07%)
Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management -- Future Expectations, Projections Moving into 2018

In new a independent research report released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UGI Corporation (NYSE:UGI),...

OLN : 37.15 (+2.51%)
AIMT : 35.58 (+2.07%)
PRTY : 12.45 (+0.40%)
UGI : 47.56 (-0.29%)
WM : 80.87 (-0.06%)
ODFL : 123.22 (+2.32%)
Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine...

AIMT : 35.58 (+2.07%)
Aimmune Therapeutics to Participate in Four Investor Conferences in November

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management...

AIMT : 35.58 (+2.07%)
Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial

---- First Peer-Reviewed Publication of Efficacy and Safety of an Industry-Sponsored Food Allergy Trial --

AIMT : 35.58 (+2.07%)
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut...

AIMT : 35.58 (+2.07%)
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi's Dupilumab for Peanut Allergy

---- Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment --

AIMT : 35.58 (+2.07%)
Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?

Investors in Aimmune Therapeutics (AIMT) need to pay close attention to the stock based on moves in the options market lately.

AIMT : 35.58 (+2.07%)
Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher

Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes.

AIMT : 35.58 (+2.07%)
LGND : 130.03 (-0.36%)
Arcus Biosciences Appoints Kate Falberg to Its Board of Directors

Arcus Biosciences, a biotechnology company focused on the discovery and development of innovative cancer immunotherapies, today announced the appointment of Kathryn ("Kate") Falberg to its...

AIMT : 35.58 (+2.07%)
URGN : 40.91 (-2.13%)
TTD : 51.92 (+3.02%)
AXON : 5.46 (+1.49%)
AMGN : 169.84 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 36.32
1st Resistance Point 35.95
Last Price 35.58
1st Support Level 34.96
2nd Support Level 34.34

See More

52-Week High 37.50
Last Price 35.58
Fibonacci 61.8% 29.28
Fibonacci 50% 26.74
Fibonacci 38.2% 24.19
52-Week Low 15.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart